{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:28:41Z","timestamp":1787149721446,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Induction immunosuppression reduces early rejection after solid organ transplantation but may increase long-term malignancy risk, including keratinocyte carcinoma. Antithymocyte globulin is commonly used as a lymphocyte-depleting induction agent, yet its relative risk compared with other strategies remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the association between antithymocyte globulin induction therapy and keratinocyte carcinoma risk in adult solid organ transplant recipients compared with no induction, nondepleting agents, and other lymphocyte-depleting therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>PubMed, EMBASE, and MEDLINE were searched from January 1997 to February 2024. Observational studies and randomized trials reporting keratinocyte carcinoma outcomes in adult recipients exposed to antithymocyte globulin were included. Risk of bias was assessed using validated tools. Random-effects meta-analyses using risk ratios with 95% confidence intervals were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twelve studies including 56,159 recipients with a weighted mean follow-up of 7.27 years were analyzed. Antithymocyte globulin induction was not associated with increased keratinocyte carcinoma risk compared with no induction. Lower risk was observed compared with alemtuzumab and OKT3. No significant difference in risk was observed compared with nondepleting anti-CD25 agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Antithymocyte globulin induction does not increase keratinocyte carcinoma risk compared with no induction and is associated with lower risk than more potent lymphocyte-depleting agents after solid organ transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005239","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:21Z","timestamp":1787148021000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Keratinocyte Carcinoma Risk: Antithymocyte Globulin vs. Other Induction Therapy in Solid Organ Transplant Patients"],"prefix":"10.1097","author":[{"given":"Rishab","family":"Revankar","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Virginia School of Medicine, Charlottesville, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Sivagnanalingam","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Rojas","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York;"},{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pugliano-Mauro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"R1-20260819","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/164_2021_570","article-title":"Induction therapy and therapeutic antibodies","volume":"272","author":"Nikolova","year":"2022","journal-title":"Handbook Exp Pharmacol"},{"key":"R2-20260819","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1016\/j.transproceed.2009.06.184","article-title":"Induction with and without antithymocyte globulin combined with cyclosporine\/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials","volume":"41","author":"Tian","year":"2009","journal-title":"Transplant Proc"},{"key":"R3-20260819","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1111\/ajt.15513","article-title":"The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes","volume":"19","author":"Bittermann","year":"2019","journal-title":"Am J Transplant"},{"key":"R4-20260819","doi-asserted-by":"crossref","first-page":"322","DOI":"10.12659\/AOT.908243","article-title":"A review of induction with rabbit antithymocyte globulin in pediatric heart transplant recipients","volume":"23","author":"Schweiger","year":"2018","journal-title":"Ann Transpl"},{"key":"R5-20260819","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajt.13884","article-title":"Induction therapy for kidney transplant recipients: do we still need Anti-IL2 receptor monoclonal antibodies?","volume":"17","author":"Hellemans","year":"2017","journal-title":"Am J Transplant"},{"key":"R6-20260819","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.intimp.2011.07.012","article-title":"Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin","volume":"11","author":"Lib\u00f3rio","year":"2011","journal-title":"Int Immunopharmacology"},{"key":"R7-20260819","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/SLA.0000000000000496","article-title":"Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation","volume":"259","author":"Pilch","year":"2014","journal-title":"Ann Surg"},{"key":"R8-20260819","doi-asserted-by":"crossref","first-page":"e14121","DOI":"10.1111\/ctr.14121","article-title":"Induction immunosuppression and the risk of incident malignancies among older and younger kidney transplant recipients: a prospective cohort study","volume":"34","author":"Wang","year":"2020","journal-title":"Clin Transplant"},{"key":"R9-20260819","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/dth.12379","article-title":"Immunosuppressive therapy in the posttransplant period and skin cancer","volume":"29","author":"Kr\u00e1sov\u00e1","year":"2016","journal-title":"Dermatol Ther"},{"key":"R10-20260819","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/ndt\/gfac337","article-title":"Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis","volume":"38","author":"Massicotte-Azarniouch","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R11-20260819","first-page":"152","article-title":"Skin cancer in renal transplant recipients receiving different induction therapies","volume":"228","author":"Bernat-Garc\u00eda","year":"2014","journal-title":"Dermatology"},{"key":"R12-20260819","first-page":"1176","article-title":"Induction immunosuppression and risk of nonmelanoma skin cancer after heart transplantation","volume":"33","author":"Chivukula","year":"2014","journal-title":"J Heart Lung Transpl"},{"key":"R13-20260819","first-page":"339","article-title":"Malignancies after liver transplantation: incidence, risk factors, and role of immunosuppression","volume":"10","author":"Jonas","year":"1997","journal-title":"Transpl Int"},{"key":"R14-20260819","first-page":"620","article-title":"Risk of nonmelanoma skin cancer in kidney transplant recipients receiving different induction regimens","volume":"48","author":"Mart\u00ednez-Cabriales","year":"2016","journal-title":"Transpl Proc"},{"key":"R15-20260819","first-page":"1110","article-title":"Induction therapy and posttransplant malignancy in heart transplant recipients","volume":"29","author":"Molina","year":"2010","journal-title":"J Heart Lung Transpl"},{"key":"R16-20260819","first-page":"633","article-title":"Daclizumab versus antithymocyte globulin induction therapy in heart transplantation: a randomized controlled trial","volume":"33","author":"Mullen","year":"2014","journal-title":"J Heart Lung Transpl"},{"key":"R17-20260819","first-page":"2154","article-title":"Induction immunosuppression and cancer risk after heart transplantation in the United States","volume":"21","author":"Nair","year":"2021","journal-title":"Am J Transpl"},{"key":"R18-20260819","first-page":"e14789","article-title":"Induction therapy and malignancy outcomes in contemporary heart transplant recipients","volume":"37","author":"Nair","year":"2023","journal-title":"Clin Transpl"},{"key":"R19-20260819","first-page":"53","article-title":"Skin cancer in kidney transplant recipients receiving antibody induction therapy","volume":"22","author":"Stratta","year":"2008","journal-title":"Clin Transpl"},{"key":"R20-20260819","first-page":"2187","article-title":"Induction immunosuppression and skin cancer risk in kidney and kidney\u2013pancreas transplant recipients","volume":"53","author":"Tzadok","year":"2021","journal-title":"Transpl Proc"},{"key":"R21-20260819","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R22-20260819","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/bjd\/ljaf483","article-title":"Immunosuppressive regimens and skin cancer risk in solid-organ transplant recipients","volume":"194","author":"G\u00f3mez-Tom\u00e1s","year":"2025","journal-title":"Br J Dermatol"},{"key":"R23-20260819","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/cells12202441","article-title":"Immunity against non-melanoma skin cancer and the effect of immunosuppressive medication on non-melanoma skin cancer risk in solid organ transplant recipients","volume":"12","author":"Bakker","year":"2023","journal-title":"Cells"},{"key":"R24-20260819","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamadermatol.2022.0036","article-title":"Spectrum of nonkeratinocyte skin cancer risk among solid organ transplant recipients in the US","volume":"158","author":"Sargen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R25-20260819","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0190-9622(00)90154-3","article-title":"Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens","volume":"42","author":"Jensen","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R26-20260819","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/j.1524-4725.2012.02520.x","article-title":"Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management","volume":"38","author":"Tessari","year":"2012","journal-title":"Dermatol Surg"},{"key":"R27-20260819","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cnet state of immunosuppression\u201d","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R28-20260819","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/2047-1440-2-S1-S5","article-title":"Alemtuzumab induction therapy in solid organ transplantation","volume":"2","author":"Friend","year":"2013","journal-title":"Transpl Res"},{"key":"R29-20260819","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"key":"R30-20260819","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/petr.12048","article-title":"Alemtuzumab induction in pediatric kidney transplantation","volume":"17","author":"Kaabak","year":"2013","journal-title":"Pediatr Transplant"},{"key":"R31-20260819","doi-asserted-by":"crossref","first-page":"e0240929","DOI":"10.1371\/journal.pone.0240929","article-title":"Induction therapy in kidney transplant recipients: description of the practices according to the calendar period from the French multicentric DIVAT cohort","volume":"15","author":"Boucquemont","year":"2020","journal-title":"PLoS One"},{"key":"R32-20260819","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/tri.13079","article-title":"Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice","volume":"31","author":"Dharnidharka","year":"2018","journal-title":"Transpl Int"},{"key":"R33-20260819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/957549","article-title":"Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days?","volume":"2010","author":"Hardinger","year":"2010","journal-title":"J Transplant"},{"key":"R34-20260819","doi-asserted-by":"crossref","first-page":"12560","DOI":"10.1038\/s41598-023-39353-6","article-title":"Evaluating anti-thymocyte globulin induction doses for better allograft and patient survival in Asian kidney transplant recipients","volume":"13","author":"Shim","year":"2023","journal-title":"Sci Rep"},{"key":"R35-20260819","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/TP.0000000000000449","article-title":"Association of antibody induction immunosuppression with cancer after kidney transplantation","volume":"99","author":"Hall","year":"2015","journal-title":"Transplantation"},{"key":"R36-20260819","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tri.13520","article-title":"Initial skin cancer screening for solid organ transplant recipients in the United States: delphi method development of expert consensus guidelines","volume":"32","author":"Crow","year":"2019","journal-title":"Transpl Int"},{"key":"R37-20260819","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1111\/ajt.15224","article-title":"Skin cancer screening after solid organ transplantation: a survey of practices in Canada","volume":"19","author":"Lam","year":"2019","journal-title":"Am J Transpl"},{"key":"R38-20260819","doi-asserted-by":"crossref","first-page":"416","DOI":"10.21037\/atm.2020.02.126","article-title":"Malignancy after lung transplantation","volume":"8","author":"Shtraichman","year":"2020","journal-title":"Ann Transl Med"},{"key":"R39-20260819","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin cancers in organ transplant recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transplant"},{"key":"R40-20260819","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","article-title":"Incidence of and risk factors for skin cancer in organ transplant recipients in the United States","volume":"153","author":"Garrett","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R41-20260819","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ajt.14966","article-title":"Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: population-based cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"Am J Transplant"},{"key":"R42-20260819","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jamadermatol.2019.0692","article-title":"Incidence and risk factors of keratinocyte Carcinoma after first solid organ transplant in Ontario, Canada","volume":"155","author":"Park","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:27Z","timestamp":1787148027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005239"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005239","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}